Our whole-genome and targeted resequencing study in the hitherto largest cohort of EBV + DLBCL (NOS) in which all cases underwent rigorous central hematopathological panel review and cytogenetic workup prior to inclusion, we find a significant perturbing role of several recurrent alterations in NFκB, WNT, and IL6/JAK/STAT signaling. Here, NFKB1 is linked to diffuse large B-cell lymphoma.